JCR Pharmaceuticals Awarded Japan’s Regenerative CDMO Subsidy for Facility Expansion

• JCR Pharmaceuticals has been selected for Japan’s Regenerative CDMO Subsidy to expand its biomanufacturing infrastructure.

• The funding will support facility upgrades, equipment installation, and workforce training through to December 2027.

JCR Pharmaceuticals Co., Ltd. has been selected for the Japanese Ministry of Economy, Trade and Industry’s (METI) Regenerative CDMO Subsidy programme, the company announced on 15 July 2025. The funding will support JCR’s efforts to expand its contract manufacturing capabilities for regenerative, cell, and gene therapies.

Under the project titled JCR Regenerative Medicine CDMO Enhancement, the company will invest in facility upgrades and workforce development. The subsidy covers activities from the approval date through to 31 December 2027.

The initiative builds on JCR’s experience in regenerative medicine, including the approval of TEMCELL® HS Inj. in 2015 and the development of its AAV gene therapy platform, JUST-AAV. The platform uses JCR’s proprietary J-Brain Cargo® technology, designed to deliver therapies across the blood-brain barrier.

JCR stated that the capital investment will support both internal pipeline growth and new partnerships. The aim is to strengthen the company’s role in biomanufacturing regenerative medicine products in Japan and beyond.

The Regenerative CDMO Subsidy programme is designed to bolster domestic contract manufacturing capacity for advanced therapies and build specialised talent within Japan’s biopharmaceutical sector.